{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:04:25Z","timestamp":1784793865683,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Oncology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>5-fluorouracil (5-FU) is a widely used chemotherapy agent in gastrointestinal (GI) malignancies, but it can cause cardiotoxicity, most commonly manifesting as chest pain due to coronary vasospasm, often mimicking acute coronary syndrome. Adequate management of 5-FU-associated vasospasm is critical to ensure the necessary oncological treatment can be safely continued.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was the retrospective analysis of cases of chest pain associated with intravenous 5-FU treatment in GI cancer patients at a single institution, and to report the experiences with antianginal treatment, specifically nitrates and calcium channel blockers, administered in these cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, single-center, observational cohort study. We analyzed data of GI cancer patients treated with intravenous 5-FU between March 2024 and August 2025 who experienced chest pain during treatment. Following the institutional protocol, the chemotherapy was transiently suspended, and treatment was re-introduced under combined oral or intravenous nitrate and calcium channel blocker protection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 835 patients receiving iv 5-FU, 25 (2.9%) developed chest pain, typically after the second or third cycle of chemotherapy. Three patients presented with ST-elevation on ECG, but none of them showed significant coronary stenosis on imaging. With appropriate cardiological treatment, all 25 patients achieved symptom-free oncological treatment continuation: 19 patients with combined nitrate and calcium channel blocker therapy, 6 with monotherapy, and one of these patients required intravenous treatment under ICU monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Coronary vasospasm associated with intravenous 5-FU is a rare but clinically significant complication. Our findings, in line with the literature, suggest that the introduction of antianginal therapy successfully allowed the safe rechallenge and continuation of oncological therapy in all affected patients, which may prevent unnecessary discontinuation of life-prolonging chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Retrospectively registered (Approval No. OOI\/\u00c1lt11147-1\/2025).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-026-00526-7","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:26:28Z","timestamp":1781569588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effective management of 5-fluorouracil-induced coronary vasospasm allowing chemotherapy continuation: a single-center observational study"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4022-8417","authenticated-orcid":false,"given":"Kinga","family":"Kolossv\u00e1ry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Heltai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borb\u00e1la","family":"Sz\u00e9kely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Rubovszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"526_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaccao.2020.12.005","volume":"3","author":"A Zafar","year":"2021","unstructured":"Zafar A, Drobni ZD, Mosarla R, et al. The incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm. JACC CardioOncol. 2021;3:101\u20139.","journal-title":"JACC CardioOncol"},{"key":"526_CR2","doi-asserted-by":"publisher","first-page":"175883591878014","DOI":"10.1177\/1758835918780140","volume":"10","author":"JD Sara","year":"2018","unstructured":"Sara JD, Kaur J, Khodadadi R, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140.","journal-title":"Ther Adv Med Oncol"},{"issue":"19","key":"526_CR3","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.3390\/jcm10194426","volume":"10","author":"M Jurczyk","year":"2021","unstructured":"Jurczyk M, Kr\u00f3l M, Midro A, et al. Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management. J Clin Med. 2021;10(19):4426.","journal-title":"J Clin Med"},{"key":"526_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaccao.2020.06.012","volume":"2","author":"A Padegimas","year":"2020","unstructured":"Padegimas A, Carver JR. How to diagnose and manage patients with fluoropyrimidine-induced chest pain: a single center approach. JACC CardioOncol. 2020;2:650\u20134.","journal-title":"JACC CardioOncol"},{"key":"526_CR5","doi-asserted-by":"publisher","first-page":"1594338","DOI":"10.3389\/fcvm.2025.1594338","volume":"12","author":"A Hasnie","year":"2025","unstructured":"Hasnie A, Neace Z, Ellison K, et al. Case Report: Coronary vasospasm precipitating STEMI and polymorphic ventricular tachycardia-a case of cardiotoxicity from 5-FU based chemotherapy in a 41-year-old woman. Front Cardiovasc Med. 2025;12:1594338.","journal-title":"Front Cardiovasc Med"},{"key":"526_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.mayocp.2025.08.019","volume":"101","author":"Z Zalaquett","year":"2026","unstructured":"Zalaquett Z, Shukla N, Hajj J, et al. Cardiovascular toxicity of fluoropyrimidines: what we know. Mayo Clin Proc. 2026;101:136\u201355.","journal-title":"Mayo Clin Proc"},{"key":"526_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.15420\/icr.2019.12","volume":"14","author":"JH Chong","year":"2019","unstructured":"Chong JH, Ghosh AK. Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions. Interv Cardiol. 2019;14:89\u201394.","journal-title":"Interv Cardiol"},{"key":"526_CR8","doi-asserted-by":"publisher","first-page":"105137","DOI":"10.1016\/j.jaccas.2025.105137","volume":"30","author":"R Rana","year":"2025","unstructured":"Rana R, Wallace RL, Waksman R, et al. 5-fluorouracil-induced microvascular vasospasm diagnosed by coronary functional testing. JACC Case Rep. 2025;30:105137.","journal-title":"JACC Case Rep"},{"key":"526_CR9","doi-asserted-by":"publisher","first-page":"e0265767","DOI":"10.1371\/journal.pone.0265767","volume":"17","author":"A Zafar","year":"2022","unstructured":"Zafar A, Drobni ZD, Lei M, et al. The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm. PLoS ONE. 2022;17:e0265767.","journal-title":"PLoS ONE"},{"issue":"7\u20138","key":"526_CR10","first-page":"733","volume":"71","author":"C Collins","year":"1987","unstructured":"Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep. 1987;71(7\u20138):733\u20136.","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"526_CR11","first-page":"P151","volume":"8","author":"N Tsavaris","year":"2002","unstructured":"Tsavaris N, Kosmas C, Vadiaka M, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients. Med Sci Monit. 2002;8(6):P151\u20137.","journal-title":"Med Sci Monit"},{"issue":"1","key":"526_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","volume":"134","author":"C Kosmas","year":"2008","unstructured":"Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134(1):75\u201382.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"526_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1517\/14740330902733961","volume":"8","author":"MW Saif","year":"2009","unstructured":"Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8(2):191\u2013202.","journal-title":"Expert Opin Drug Saf"},{"key":"526_CR14","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23:e333\u2013465.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"526_CR15","doi-asserted-by":"publisher","first-page":"104750","DOI":"10.1016\/j.jaccas.2025.104750","volume":"30","author":"UV Majmudar","year":"2025","unstructured":"Majmudar UV, Dhamija K, Khan E, et al. Rechallenging Patients With Fluoropyridine-Induced Coronary Vasospasm: 5 Success Stories. JACC Case Rep. 2025;30:104750.","journal-title":"JACC Case Rep"},{"key":"526_CR16","doi-asserted-by":"publisher","first-page":"104550","DOI":"10.1016\/j.jaccas.2025.104550","volume":"30","author":"MRB Wanderley Jr.","year":"2025","unstructured":"Wanderley MRB Jr., Rizzo S, Whooley PD, et al. Rechallenge of 5-fluorouracil in a patient with coronary vasospasm unable to receive oral medications. JACC Case Rep. 2025;30:104550.","journal-title":"JACC Case Rep"},{"issue":"3","key":"526_CR17","doi-asserted-by":"publisher","first-page":"e606","DOI":"10.1634\/theoncologist.2019-0762","volume":"25","author":"I Raber","year":"2020","unstructured":"Raber I, Warack S, Kanduri J, Pribish A, et al. Fluoropyrimidine-associated cardiotoxicity: a retrospective case-control study. Oncologist. 2020;25(3):e606\u20139.","journal-title":"Oncologist"},{"key":"526_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejca.2022.02.004","volume":"166","author":"JWG Derksen","year":"2022","unstructured":"Derksen JWG, Smit KC, May AM, et al. Systematic review and non-inferiority meta-analysis of randomised phase II\/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer. Eur J Cancer. 2022;166:73\u201386.","journal-title":"Eur J Cancer"},{"issue":"2","key":"526_CR19","doi-asserted-by":"publisher","first-page":"101199","DOI":"10.1016\/j.esmoop.2023.101199","volume":"8","author":"CJA Punt","year":"2023","unstructured":"Punt CJA, Heinemann V, Maughan T, et al. Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer. ESMO Open. 2023;8(2):101199.","journal-title":"ESMO Open"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00526-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:29:26Z","timestamp":1784791766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00526-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["526"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00526-7","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"17 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"94"}}